Allie A. Rodgers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Allie A. Rodgers has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Afton L. Hassett
Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan, USA
2 shared publications - Agnes Fejer
University of Michigan-Ann Arbor, Ann Arbor, US
2 shared publications - Cherie Cofield
Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA
2 shared publications - Helen J. Burgess
Sleep and Circadian Research Laboratory, Department of Psychiatry, University of Michigan , Ann Arbor, MI
2 shared publications - Hyungjin Myra Kim
Consulting for Statistics, Computing and Analytics Research, University of Michigan, Ann Arbor, USA
2 shared publications - Jackson Mott
University of Michigan-Ann Arbor, Ann Arbor, US
2 shared publications
Latest Publications
- Open Access
- 27 March 2025
- Published by JMIR Publications Inc. in JMIR Preprints
At-Home Morning Bright Light Treatment for Chronic Nociplastic Pain: Protocol for a Randomized Clinical Trial (Preprint)
BACKGROUND Fibromyalgia, the quintessential nociplastic pain condition, affects more than 20 million Americans and results in significant disability, lost productivity, and poor quality of life, with profound individual and societal cost. As pharmacological treatment approaches offer only modest benefits and result in a high rate of discontinuation due to adverse effects, nonpharmacological interventions such as physical therapy, exercise, and cognitive behavioral therapy are recommended. However, cost and access to these treatments can create barriers to care, and engagement can be problematic. Morning bright light treatment is a promising option for improving fibromyalgia symptoms, with early studies indicating clinically meaningful improvements in fibromyalgia symptoms. OBJECTIVE This study aims to prospectively examine the potential benefits and active elements of morning bright light treatment and sleep timing stabilization for individuals with fibromyalgia in the largest randomized controlled trial to date. METHODS We will recruit 390 adults who meet diagnostic criteria for fibromyalgia and report at least mild symptoms. Participants will be randomized to one of three groups: 4 weeks of morning bright light treatment (1 hour per day, using a commercially available Re-timer device), 4 weeks of sleep timing stabilization alone (a component of morning bright light treatment, some benefit anticipated), or 4 weeks of treatment as usual, with equivalent study contact. Patient-reported outcomes of function and pain will be assessed before and after treatment, with mood, sleep quality, and morningness-eveningness examined as potential mediators of treatment effects. Social determinants of health risk will be examined as a potential moderator influencing baseline symptoms, treatment engagement, and treatment response. RESULTS Data collection began in September 2024 and is projected to end in March 2029. CONCLUSIONS Morning bright light treatment is well-positioned to be an effective nonpharmacological treatment for fibromyalgia with minimal side effects. The study findings will provide important insights relevant to the development of morning bright light treatment as an accessible treatment for chronic nociplastic pain. CLINICALTRIAL ClinicalTrials.gov NCT06567886; https://clinicaltrials.gov/study/NCT06567886 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/75060
- 27 March 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAt-Home Morning Bright Light Treatment for Chronic Nociplastic Pain: Protocol for a Randomized Clinical Trial (Preprint)
BACKGROUND Fibromyalgia, the quintessential nociplastic pain condition, affects more than 20 million Americans and results in significant disability, lost productivity, and poor quality of life, with profound individual and societal cost. As pharmacological treatment approaches offer only modest benefits and result in a high rate of discontinuation due to adverse effects, nonpharmacological interventions such as physical therapy, exercise, and cognitive behavioral therapy are recommended. However, cost and access to these treatments can create barriers to care, and engagement can be problematic. Morning bright light treatment is a promising option for improving fibromyalgia symptoms, with early studies indicating clinically meaningful improvements in fibromyalgia symptoms. OBJECTIVE This study aims to prospectively examine the potential benefits and active elements of morning bright light treatment and sleep timing stabilization for individuals with fibromyalgia in the largest randomized controlled trial to date. METHODS We will recruit 390 adults who meet diagnostic criteria for fibromyalgia and report at least mild symptoms. Participants will be randomized to one of three groups: 4 weeks of morning bright light treatment (1 hour per day, using a commercially available Re-timer device), 4 weeks of sleep timing stabilization alone (a component of morning bright light treatment, some benefit anticipated), or 4 weeks of treatment as usual, with equivalent study contact. Patient-reported outcomes of function and pain will be assessed before and after treatment, with mood, sleep quality, and morningness-eveningness examined as potential mediators of treatment effects. Social determinants of health risk will be examined as a potential moderator influencing baseline symptoms, treatment engagement, and treatment response. RESULTS Data collection began in September 2024 and is projected to end in March 2029. CONCLUSIONS Morning bright light treatment is well-positioned to be an effective nonpharmacological treatment for fibromyalgia with minimal side effects. The study findings will provide important insights relevant to the development of morning bright light treatment as an accessible treatment for chronic nociplastic pain. CLINICALTRIAL ClinicalTrials.gov NCT06567886; https://clinicaltrials.gov/study/NCT06567886 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/75060
- Open Access
- 27 March 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14
At Home Morning Bright Light Treatment for Chronic Nociplastic Pain: A Protocol for A Randomized Clinical Trial (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
- 27 March 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14
Open AccessAt Home Morning Bright Light Treatment for Chronic Nociplastic Pain: A Protocol for A Randomized Clinical Trial (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).